SCHEMBL26075230

SCHEMBL26075230

COc1ccc(-c2ccc(-c3cc(C)c4cc(F)ccc4n3)cc2F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 2/20 0.54
▸ ACACA Q13085 1/20 0.48
▸ AURKA O14965 1/20 0.46
▸ AURKB Q96GD4 1/20 0.46
▸ ACP1 P24666 3/20 0.45
▸ DHODH Q02127 4/20 0.45
▸ SQOR Q9Y6N5 1/20 0.44
▸ AMY1A P0DUB6 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ NT5E P21589 1/20 0.42
▸ APP P05067 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075308 0.89 DHODH (0.55) PLA2G2AACACADHODHMEN1KMT2A
SCHEMBL26075865 0.88 ACACA (0.46) PLA2G2AACACAAURKAAURKBACP1
SCHEMBL26075224 0.88 AURKA (0.62) PLA2G2AACACAAURKAAURKBACP1
SCHEMBL26075136 0.88 ESR1 (0.50) DHODHMEN1KMT2A
SCHEMBL26074120 0.87 PLA2G2A (0.64) PLA2G2AACACAAURKAAURKBACP1
SCHEMBL26075255 0.87 PLA2G2A (0.41) PLA2G2AACP1DHODHMEN1KMT2A
SCHEMBL26075130 0.87 HMOX1 (0.43) PLA2G2ADHODHMEN1KMT2AMAPT
SCHEMBL26075282 0.87 DHODH (0.43) PLA2G2AACP1DHODHMEN1KMT2A
SCHEMBL26075327 0.87 SQOR (0.42) PLA2G2AACP1DHODHSQORMEN1
SCHEMBL26075335 0.86 ACP1 (0.50) PLA2G2AACACAAURKAAURKBACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PLA2G2A 1679/4885ACACA 1205/4885AURKA 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback